Quarterly Financial Results

Vimta Labs Reports Q1 FY27 Results with 13.7% YoY Growth in Total Income; EBITDA Margin Sustains Above 36%

NSE

vimtalabs

BSE

524394

Vimta Labs Limited reported a steady performance for Q1 FY27, with Total Income rising 13.7% YoY to ₹1,129 million. EBITDA increased 16.0% YoY to ₹411 million, while Profit After Tax (PAT) grew 11.4% YoY to ₹210 million.
The company maintained industry-leading profitability with an EBITDA margin of 36.4% despite a marginal sequential decline due to higher operating expenses and continued investments in business expansion.

PRICE-SENSITIVE TRIGGER

Event: Vimta Labs announced its Q1 FY27 financial results and released the investor presentation for the quarter ended June 30, 2026.

Type: Quarterly Financial Results

Impact: Positive

Immediate Effect: The company delivered double-digit growth in revenue, EBITDA and PAT on a year-on-year basis while maintaining healthy operating margins and continuing investments in laboratory infrastructure and capabilities.

Metrics:

Key Metrics:

Revenue from Operations: ₹1,091 million (vs ₹976 million YoY)
Total Income: ₹1,129 million (+13.7% YoY, +0.8% QoQ)
EBITDA: ₹411 million (+16.0% YoY, -2.4% QoQ)
EBITDA Margin: 36.4% (vs 35.7% YoY; 37.6% QoQ)
Profit Before Tax (PBT): ₹283 million (+12.2% YoY, -2.4% QoQ)
PBT Margin: 25.1%
Profit After Tax (PAT): ₹210 million (+11.4% YoY, -0.3% QoQ)
PAT Margin: 18.6% (vs 19.0% YoY)
Basic EPS: ₹4.7 (+11.0% YoY)
CAPEX (Cash Outflow): ₹180 million during Q1 FY27.

Segment Performance:

Vimta Labs continues to derive revenue from multiple scientific testing and research businesses, including:

Drug Discovery & Development Services
Pharma Analytical Services
Clinical Research
Preclinical Research
Food, Agriculture & Environmental Testing
Electronics & Electrical Testing & Certification

The investor presentation does not provide a segment-wise revenue breakup for the quarter.

Highlight:

Vimta Labs achieved double-digit YoY growth across revenue, EBITDA and PAT while sustaining an EBITDA margin above 36%, reflecting resilient operational performance.

What Happened ?

Vimta Labs reported a stable first quarter of FY27 with consistent revenue growth supported by its diversified contract research and testing portfolio.

Total income increased to ₹1,129 million, while EBITDA reached ₹411 million with a margin of 36.4%. PAT stood at ₹210 million, reflecting continued profitability despite ongoing investments in infrastructure and business expansion.

The company also continued capital expenditure during the quarter with ₹180 million invested towards expanding capabilities and laboratory infrastructure.

Key details

Q1 FY27 Business Performance:

Total income crossed ₹1.12 billion, recording 13.7% annual growth.
EBITDA increased at a faster pace than revenue, demonstrating continued operating efficiency.
PAT crossed ₹210 million despite higher depreciation associated with ongoing capital investments.
Basic EPS improved to ₹4.7 compared with ₹4.2 in Q1 FY26.

Operational Highlights:

Vimta Labs continued strengthening its scientific research and testing platform across:

Pharmaceutical analytical services.
Clinical research.
Preclinical research.
Biologics contract research and development.
Food, agriculture and environmental testing.
Electronics and electrical product testing.

The company also continued investing in laboratory expansion to support future capacity growth.

Business Strength:

The investor presentation highlights several competitive strengths:

More than 42 years of industry experience.
Approximately 600,000 sq. ft. of laboratory infrastructure.
1,400+ multidisciplinary professionals.
10 laboratories and offices across India.
Around 100 successful regulatory audits.

These capabilities position the company to serve pharmaceutical, biotechnology, food, environmental and electronics industries.

Long-Term Financial Track Record:

The presentation indicates consistent financial expansion over FY22–FY26:

Total Income CAGR: 10.5%
EBITDA CAGR: 16.2%
PAT CAGR: 17.0%
Debt-to-Equity reduced to 0.01
FY26 ROCE: 21%
FY26 ROE: 17%

The long-term trend reflects improving profitability alongside a conservative balance sheet.

Note:

The investor presentation does not announce any new acquisitions, large customer contracts, fundraising activities or corporate actions during the quarter. The disclosure primarily focuses on quarterly financial performance and business updates.

Risk Analysis

Summary:

Vimta Labs continues to maintain strong profitability and revenue growth. However, the slight sequential moderation in EBITDA and PAT indicates ongoing cost pressures associated with expansion and operational investments.

Key Risks:

EBITDA margin moderated sequentially from 37.6% to 36.4%.
PAT margin declined marginally from 19.0% to 18.6%.
Continued capital expenditure could increase depreciation and near-term cost pressures.
Growth remains dependent on sustained demand across pharmaceutical research, testing and regulatory services.
Regulatory compliance remains critical given the company’s highly regulated business model.

Worst Case:

If customer demand weakens or laboratory utilization declines while expansion costs remain elevated, profitability margins could compress despite revenue growth.

Risk Level: Medium

Company Commentary

Vimta Labs continued delivering profitable growth across its diversified testing and contract research businesses.
The company maintained strong operating margins while investing in future laboratory infrastructure.
Management highlighted continued investments in scientific capabilities, technology and research infrastructure.
Vimta reiterated its focus on expanding pharmaceutical, biologics, food, environmental and electronics testing services to support long-term growth.
The presentation also emphasized the company’s extensive regulatory accreditations, scientific expertise and nationwide laboratory network as key competitive advantages.

Official Exchange Filing: Vimta Labs Limited

Support our work by sharing